Total Payments
$702,961
2024 Payments
$198,512
Companies
50
Transactions
1,343
Medicare Patients
9,206
Medicare Billing
$704,395
Payment Breakdown by Category
Other$559,765 (79.6%)
Consulting$50,930 (7.2%)
Travel$48,657 (6.9%)
Food & Beverage$27,370 (3.9%)
Research$15,695 (2.2%)
Education$544.06 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $559,265 | 266 | 79.6% |
| Consulting Fee | $50,930 | 31 | 7.2% |
| Travel and Lodging | $48,657 | 191 | 6.9% |
| Food and Beverage | $27,370 | 829 | 3.9% |
| Unspecified | $15,695 | 16 | 2.2% |
| Education | $544.06 | 9 | 0.1% |
| Honoraria | $500.00 | 1 | 0.1% |
Payments by Type
General
$687,266
1,327 transactions
Research
$15,695
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $325,653 | 540 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $147,540 | 107 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $51,963 | 74 | $0 (2024) |
| GENZYME CORPORATION | $51,734 | 55 | $0 (2024) |
| ABBVIE INC. | $27,080 | 75 | $0 (2024) |
| Incyte Corporation | $24,325 | 41 | $0 (2024) |
| PFIZER INC. | $22,480 | 55 | $0 (2024) |
| UCB, Inc. | $10,460 | 79 | $0 (2024) |
| Next Science LLC | $7,895 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $6,282 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $198,512 | 272 | E.R. Squibb & Sons, L.L.C. ($84,463) |
| 2023 | $167,000 | 237 | E.R. Squibb & Sons, L.L.C. ($62,622) |
| 2022 | $64,094 | 182 | Lilly USA, LLC ($47,483) |
| 2021 | $24,720 | 62 | Lilly USA, LLC ($24,109) |
| 2020 | $17,014 | 41 | Lilly USA, LLC ($14,817) |
| 2019 | $96,789 | 199 | Lilly USA, LLC ($87,984) |
| 2018 | $83,903 | 178 | Lilly USA, LLC ($77,529) |
| 2017 | $50,929 | 172 | Lilly USA, LLC ($46,477) |
All Payment Transactions
1,343 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $123.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $0.72 | General |
| Category: Immunology | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $14.68 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Education | In-kind items and services | $8.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $4.86 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $3.77 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $0.43 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $7.27 | General |
| 12/02/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $6.26 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $65.41 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Immunology | ||||||
| 11/20/2024 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $69.12 | General |
| 11/20/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: DERMATOLOGY | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,313.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $6.69 | General |
| 11/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,967.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $168.37 | General |
| Category: Immunology | ||||||
| 11/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $87.59 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis (PROAK) | Almirall LLC | $6,050 | 2 |
| Keloid Study | Next Science LLC | $5,895 | 3 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $2,123 | 1 |
| A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | SANOFI PASTEUR INC. | $1,627 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,375 | 2,643 | $391,258 | $120,982 |
| 2022 | 22 | 1,417 | 2,492 | $396,547 | $128,812 |
| 2021 | 22 | 2,849 | 4,906 | $669,300 | $222,263 |
| 2020 | 23 | 3,565 | 5,768 | $692,243 | $232,338 |
Total Patients
9,206
Total Services
15,809
Medicare Billing
$704,395
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 360 | 553 | $86,268 | $33,032 | 38.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 98 | 177 | $42,657 | $15,688 | 36.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 130 | 154 | $30,800 | $12,333 | 40.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 131 | 174 | $29,928 | $10,625 | 35.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 201 | 269 | $51,110 | $9,379 | 18.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 15 | 20 | $9,720 | $6,058 | 62.3% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 13 | 16 | $14,944 | $5,222 | 34.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 67 | 67 | $19,095 | $4,731 | 24.8% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 17 | 19 | $11,457 | $4,177 | 36.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 149 | 882 | $38,808 | $3,994 | 10.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 23 | 29 | $17,574 | $3,564 | 20.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 38 | 64 | $5,952 | $2,437 | 40.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 43 | 57 | $6,270 | $2,104 | 33.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $6,030 | $1,923 | 31.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 20 | 21 | $4,557 | $1,729 | 37.9% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 12 | 14 | $8,414 | $1,528 | 18.2% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 15 | 17 | $3,485 | $1,505 | 43.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 79 | $4,029 | $861.10 | 21.4% |
| Q0112 | All potassium hydroxide (koh) preparations | Office | 2023 | 13 | 16 | $160.00 | $91.37 | 57.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 221 | 339 | $81,586 | $29,391 | 36.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 283 | 402 | $62,061 | $26,187 | 42.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 132 | 156 | $26,691 | $10,678 | 40.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 188 | 242 | $45,243 | $9,241 | 20.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 80 | 93 | $18,600 | $7,765 | 41.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $22,681 | $5,719 | 25.2% |
About Dr. Michael Bernhardt, MD
Dr. Michael Bernhardt, MD is a Dermatology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386695054.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Bernhardt, MD has received a total of $702,961 in payments from pharmaceutical and medical device companies, with $198,512 received in 2024. These payments were reported across 1,343 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($559,265).
As a Medicare-enrolled provider, Bernhardt has provided services to 9,206 Medicare beneficiaries, totaling 15,809 services with total Medicare billing of $704,395. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Jacksonville, FL
- Active Since 05/15/2006
- Last Updated 10/25/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1386695054
Products in Payments
- TALTZ (Drug) $312,329
- DUPIXENT (Biological) $103,102
- Sotyktu (Drug) $44,520
- RINVOQ (Biological) $26,012
- OPZELURA (Drug) $23,209
- CIBINQO (Drug) $21,602
- BlastX (Device) $7,895
- Klisyri (Drug) $6,090
- COSENTYX (Biological) $5,135
- Bimzelx (Biological) $4,912
- VTAMA (Drug) $3,376
- ACZONE (Drug) $2,151
- TREMFYA (Drug) $2,093
- Xolair (Biological) $1,873
- EUCRISA (Drug) $801.29
- COSENTYX (Drug) $615.67
- Otezla (Drug) $582.25
- Cimzia (Drug) $534.76
- Zoryve (Drug) $503.31
- SKYRIZI (Biological) $490.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Jacksonville
Dr. Pearl Kwong, Md Phd, MD PHD
Dermatology — Payments: $2.8M
Dermatology $2.8M
Kristen Stewart, M.d, M.D
Dermatology — Payments: $107,300
Dermatology $107,300
Jason Sluzevich, Md, MD
Dermatology — Payments: $61,523
Dermatology $61,523
Dr. Douglas Robins, Md, MD
Dermatology — Payments: $24,873
Dermatology $24,873
Jean Mcclintock, Md, MD
Dermatology — Payments: $14,036
Dermatology $14,036
John Morello, M.d, M.D
Dermatology — Payments: $12,575
Dermatology $12,575